Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patient Safety First: Indian Regulator Takes Steps To Tighten Grip Over Site Inspections, Ensure Data Credibility

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - As India moves rapidly to become an integral part of large-scale global clinical trials, the Central Drugs Standard Control Organization under the Ministry of Health and Family Welfare has declared a set of new guidelines to ensure adequate safety of trial participants

You may also be interested in...



Pfizer, Lilly, Sanofi, Amgen And Others Named In Indian Clinical Trial Death Compensation Inquiry

The news of the health ministry probe earlier this month stirred debate about the gaping holes in Indian clinical trial laws and the country's loose enforcement framework, particularly as clinical trial projects flow rapidly into the country.

Pfizer, Lilly, Sanofi, Amgen And Others Named In Indian Clinical Trial Death Compensation Inquiry

The news of the health ministry probe earlier this month stirred debate about the gaping holes in Indian clinical trial laws and the country's loose enforcement framework, particularly as clinical trial projects flow rapidly into the country.

Pfizer, Lilly, Sanofi, Amgen And Others Implicated In Indian Clinical Trial Compensation Investigation; Are Ethics Committees To Blame?

MUMBAI - India's Health Ministry is calling on multinational drug companies operating in India - including Pfizer Inc., Eli Lilly & Co., Amgen Inc., Bristol-Myers Squibb Co., Boehringer Ingelheim GMBH, Sanofi, and Quintiles Transnational Corp. - to explain why they have not provided compensation to the families of 26 patients who died during clinical trials in the last year. A recent health ministry investigation found that out of 671 cases of reported deaths allegedly involving clinical trials - and involving as many as 44 companies - only three were compensated, but companies suggest regulators should look to India's ethics committees for answers

Related Content

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel